Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | CASR | P41180 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SI | P14410 | 2/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18853749 | 0.88 | CASR (0.48) | SMN1; SMN2NPSR1LOXL2IDO1PPARA | |
| SCHEMBL799878 | 0.86 | NPC1 (0.51) | SMN1; SMN2PPARACASRNPC1RAB9A | |
| SCHEMBL24962521 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2NPSR1LOXL2IDO1PPARA | |
| SCHEMBL20312953 | 0.83 | SMN1; SMN2 (0.50) | SMN1; SMN2NPSR1LOXL2IDO1PPARA | |
| Propionic Acid SCHEMBL10811452 | 0.82 | PPARA (0.49) | SMN1; SMN2NPSR1LOXL2IDO1PPARA | |
| SCHEMBL7239065 | 0.80 | CASR (0.49) | SMN1; SMN2CASRNPC1RAB9AGAA | |
| SCHEMBL2705399 | 0.80 | CASR (0.44) | CASRHDAC6 | |
| SCHEMBL2090627 | 0.79 | CASR (0.37) | SMN1; SMN2PPARACASRHDAC6NPC1 | |
| SCHEMBL21652203 | 0.79 | CASR (0.38) | SMN1; SMN2NPSR1CASRHDAC6NPC1 | |
| SCHEMBL21652286 | 0.79 | PPARA (0.51) | PPARACASRHDAC6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129814-B2 | Antimicrobial agents | TAXIS PHARMACEUTICALS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
| US-10544092-B2 | Malononitrile oxime ether compound and use thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180179225-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-06-28 | — | — | US | disclosed |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | THE FEINSTEIN INST MEDICAL RES (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160367531-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-12-22 | — | — | US | disclosed |
| US-9458150-B2 | Antimicrobial agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-10-04 | — | — | US | disclosed |
| US-9221841-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150307517-A1 | ANTIMICROBIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1336/4885NPSR1 4169/4885LOXL2 4456/4885 |
| US-10544092-B2 | Malononitrile oxime ether compound and use thereof | ME1, MAL2, ME3 | SMN1; SMN2 1799/4885NPSR1 4442/4885LOXL2 552/4885 |
| US-11129814-B2 | Antimicrobial agents | MRPL21, SPOUT1, LSS | SMN1; SMN2 4451/4885NPSR1 4074/4885LOXL2 3204/4885 |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | SMN1; SMN2 4282/4885NPSR1 149/4885LOXL2 3109/4885 |
| US-20160367531-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | SMN1; SMN2 2119/4885NPSR1 966/4885LOXL2 4435/4885 |
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | SMN1; SMN2 4018/4885NPSR1 2441/4885LOXL2 4245/4885 |
| US-20150307517-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | SMN1; SMN2 2119/4885NPSR1 966/4885LOXL2 4435/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1710/4885NPSR1 3444/4885LOXL2 4656/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | SMN1; SMN2 1336/4885NPSR1 4169/4885LOXL2 4456/4885 |
| US-20170136007-A1 | NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRM5 | SMN1; SMN2 468/4885NPSR1 205/4885LOXL2 2934/4885 |
| US-20180179225-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | SMN1; SMN2 2119/4885NPSR1 966/4885LOXL2 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.